New therapeutic effects of cilostazol in patients with ischemic disorders

Current Vascular Pharmacology

Volumn 13, Issue 3, 2015, Pages 399-404

  Biscetti, Federico ^a   Ferraccioli, Gianfranco ^a   Flex, Andrea ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Angiogenesis; Cilostazol; Peripheral arterial disease; Vascular endothelial growth factor

Indexed keywords

CELL ADHESION MOLECULE; CILOSTAZOL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE TRANSPORTER 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; LIPID HYDROPEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PROSTAGLANDIN E2; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIAL PROGENITOR CELL; HUMAN; INFLAMMATION; MULTICENTER STUDY (TOPIC); NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; VASODILATATION; ISCHEMIA;

HUMANS; ISCHEMIA; TETRAZOLES; VASODILATOR AGENTS;

EID: 84937119184     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666141125123743     Document Type: Article

References (53)

1. [1] Faxon DP, Creager MA, Smith SC, et al. Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2004; 109(21): 2595-604.
2. [2] Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35(7A): 1144-9.
3. [3] Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72(4): 634-46.
4. [4] Wada T, Onogi Y, Kimura Y, et al. Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions. Eur J Pharmacol 2013; 707(1-3): 120-9.
5. [5] Schrör K. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4(Suppl 2): S14-9.
6. [6] Igawa T, Tani T, Chijiwa T, et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990; 57(4): 617-23.
7. [7] Park SY, Lee JH, Kim KY, et al. Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptorgamma transcription. Atherosclerosis 2008; 201(2): 258-65.
8. [8] Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A. Peroxisome proliferator-activated receptors and angiogenesis. Nutr Metab Cardiovasc Dis 2009; 19(11): 751-9.
9. [9] Ahmadian M, Suh JM, Hah N, et al. PPAR signaling and metabolism: the good, the bad and the future. Nat Med 2013; 19(5): 557-66.
10. [10] Biscetti F, Pecorini G, Arena V, et al. Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPAR. Mol Cell Endocrinol 2013; 381(1-2): 80-7.
11. [11] Huang JV, Greyson CR, Schwartz GG. PPAR- as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res 2012; 53(9): 1738-54.
12. [12] Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Taskén K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 2002; 14(1): 1-9.
13. [13] Yasunaga K, Mase K. Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease. Arzneimittelforschung 1985; 35(7A): 1186-8.
14. [14] Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K. Inhibition of platelet aggregation and the release of Pselectin from platelets by cilostazol. Thromb Res 2001; 101(6): 445-53.
15. [15] Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A-and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006; 189(2): 350-7.
16. [16] Jeong YH, Hwang JY, Kim IS, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010; 3(1): 17-26.
17. [17] Douglas JS, Holmes DR, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112(18): 2826-32.
18. [18] Kim HL, Suh JW, Lee SP, et al. Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation. Circ J 2014.
19. [19] Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003; 38(4): 710-3.
20. [20] Ding D. Cilostazol reduces morbidity but not mortality secondary to cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurol Sci 2014; 340(1-2): 243-4.
21. [21] Nakase T, Sasaki M, Suzuki A. The effect of acute medication with cilostazol, an anti-platelet drug, on the outcome of small vessel brain infarction. J Stroke Cerebrovasc Dis 2014; 23(6): 1409-15.
22. [22] Qian Y, Bi Q. Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. Eur J Med Res 2013; 18: 53.
23. [23] Nakagawa I, Wada T, Park HS, et al. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis. J Vasc Surg 2014; 59(3): 761-7.
24. [24] Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005; 6(4): 33-40.
25. [25] Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998; 18(12): 1942-7.
26. [26] Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother 2011; 12(4): 647-55.
27. [27] Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008(1): CD003748.
28. [28] Song PS, Song YB, Yang JH, et al. Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry. Heart Vessels 2014; [Epub ahead of print]
29. [29] Youn YJ, Lee JW, Ahn SG, et al. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. Am Heart J 2014; 167(2): 241-8.e1.
30. [30] Watanabe K, Nakase H, Kimura Y. Effect of cilostazol on experimental cerebral infarction in rabbits. Arzneimittelforschung 1986; 36(7): 1022-4.
31. [31] Kohda N, Tani T, Nakayama S, et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 1999; 96(4): 261-8.
32. [32] Lee DH, Lee HR, Shin HK, et al. Cilostazol enhances integrindependent homing of progenitor cells by activation of cAMPdependent protein kinase in synergy with Epac1. J Neurosci Res 2011; 89(5): 650-60.
33. [33] Chao TH, Tseng SY, Chen IC, et al. Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease. Int J Cardiol 2014; 172(2): e371-4.
34. [34] Kawabe-Yako R, Ii M, Masaaki I, Masuo O, Asahara T, Itakura T. Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model. PLoS One 2011; 6(9): e24646.
35. [35] Kim HY, Lee SW, Park SY, et al. Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance. Life Sci 2012; 91(7-8): 250-7.
36. [36] Park SY, Lee SW, Baek SH, et al. Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis. Br J Pharmacol 2013; 168(6): 1401-11.
37. [37] Jung WK, Lee DY, Park C, et al. Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases. Br J Pharmacol 2010; 159(6): 1274-85.
38. [38] Tsai CS, Lin FY, Chen YH, et al. Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J Cell Biochem 2008; 103(1): 54-66.
39. [39] Lee C, Nelson PR. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication. Vasc Endovascular Surg 2014; 48(3): 224-9.
40. [40] Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113(11): e463-654.
41. [41] Biscetti F, Ghirlanda G, Flex A. Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration. Curr Vasc Pharmacol 2011; 9(6): 677-81.
42. [42] Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 2005; 90(3): 315-26.
43. [43] Lee TM, Su SF, Tsai CH, Lee YT, Wang SS. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clin Sci (Lond) 2001; 101(3): 305-11.
44. [44] Chao TH, Tseng SY, Li YH, et al. A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clin Sci (Lond) 2012; 123(3): 147-59.
45. [45] Biscetti F, Pecorini G, Straface G, et al. Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. Int J Cardiol 2013; 167(3): 910-6.
46. [46] Biscetti F, Straface G, De Cristofaro R, et al. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 2010; 59(6): 1496-505.
47. [47] Biscetti F, Straface G, Arena V, et al. Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. Cardiovasc Diabetol 2009; 8: 49.
48. [48] Biscetti F, Gaetani E, Flex A, et al. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 2008; 57(5): 1394-404.
49. [49] Huh JH, Seok H, Lee BW, Kang ES, Lee HC, Cha BS. Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event. Endocrine 2014; 47(1): 138-45.
50. [50] Tang WH, Lin FH, Lee CH, et al. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine 2014; 45(2): 293-301.
51. [51] Biscetti F, Pecorini G, Arena V, et al. Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARy. Mol Cell Endocrinol 2013; 381(1-2): 80-7.
52. [52] Biscetti F, Pola R. Endothelial progenitor cells and angiogenesis join the PPARty. Circ Res 2008; 103(1): 7-9.
53. [53] Biscetti F, Gaetani E, Flex A, et al. Peroxisome proliferatoractivated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation. J Vasc Res 2009; 46(2): 103-8.